Leukemia & Lymphoma最新文献_第3页

Optimal timing of allogeneic hematopoietic stem cell transplant in MDS. MDS患者异基因造血干细胞移植的最佳时机。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-19 DOI: 10.1080/10428194.2025.2514662

Kristin Rathje, Nicolaus Kröger

{"title":"Optimal timing of allogeneic hematopoietic stem cell transplant in MDS.","authors":"Kristin Rathje, Nicolaus Kröger","doi":"10.1080/10428194.2025.2514662","DOIUrl":"10.1080/10428194.2025.2514662","url":null,"abstract":"Myelodysplastic neoplasms (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, dysplasia, and a significant risk of progression to acute myeloid leukemia. Allogeneic hematopoietic stem cell transplant (HSCT) remains the only potentially curative therapy for MDS, particularly for higher-risk disease, but its success depends heavily on the timing of the procedure. This review explores the evolving evidence and decision models guiding the optimal timing of HSCT, balancing the risks of disease progression and transplant-related morbidity and mortality. Key considerations include advancements in disease-specific and transplant-specific risk stratification, such as the IPSS-M and transplant-specific scoring systems, which integrate clinical, cytogenetic, and molecular data to personalize timing decisions. Improvements in haploidentical HSCT and supportive care have expanded the feasibility and safety of HSCT for diverse patient populations, including the elderly. Prospective trials underscore the survival benefits of HSCT over non-transplant approaches for higher-risk MDS, while ongoing studies aim to address uncertainties in pretreatment, post-transplant maintenance therapy, and donor selection. By synthesizing these developments, this review provides practical insights into optimizing HSCT timing to improve outcomes for MDS patients.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1788-1800"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models. 在小鼠模型中，吸烟与骨髓增生异常综合征和造血改变的预后不良相关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-09 DOI: 10.1080/10428194.2025.2513675

Tanya Verma, Srabani Sahu, Kith Pradhan, Ritesh Aggarwal, Shanisha Gordon-Mitchell, Sakshi Jasra, Seyedeh Shareh Dehghani, Hui Zhang, Mason Spodek, Ioannis Mantzaris, Marina Konopleva, Mendel Goldfinger, Amit Verma, Dean Hosgood, Divij Verma, Aditi Shastri, Yiyu Zou

引用次数: 0

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials. 抗cd38单克隆抗体在新诊断多发性骨髓瘤患者中的疗效和安全性：基于随机对照试验的最新系统评价和荟萃分析

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-12 DOI: 10.1080/10428194.2025.2512031

Zujie Lin, Ruijun Dong, Wenxiang Zhang, Rui Liu, Bingjie Fu, Aili He

{"title":"Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials.","authors":"Zujie Lin, Ruijun Dong, Wenxiang Zhang, Rui Liu, Bingjie Fu, Aili He","doi":"10.1080/10428194.2025.2512031","DOIUrl":"10.1080/10428194.2025.2512031","url":null,"abstract":"This meta-analysis of eight phase 3 rcts assessed efficacy and safety of anti-cd38 monoclonal antibodies (mabs) in patients with newly diagnosed multiple myeloma (ndmm). anti-cd38 mabs significantly improved progression-free survival (pfs: HR 0.50, 95% CI 0.42-0.59) and overall survival (OS: HR 0.63, 95% CI 0.55-0.71) in the overall population, alongside enhanced minimal residual disease (MRD) negativity rates (RR 1.85, 95% CI 1.43-2.39). While PFS benefits were universal across subgroups, OS showed no improvement in high-risk, ISS-I, or hepatic impairment subgroups, and non-IgG subtypes lacked MRD benefit. Safety analyses demonstrated an elevated risk of multiple infection-related adverse events in the entire cohort. The risk of second primary malignancies (SPMs) also increased (RR 1.44, 95% CI 1.14-1.81). Although anti-CD38 mAbs enhance treatment efficacy with manageable toxicity, the absence of OS benefit in high-risk subgroups warrants attention, and the risk of SPMs needs further investigation.Prospero registration number: CRD42024599221.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1839-1849"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Childhood body mass index at diagnosis and its association with non-Hodgkin lymphoma in the United States: a children's oncology group data analysis project. 美国儿童诊断时的体重指数及其与非霍奇金淋巴瘤的关系：一个儿童肿瘤组数据分析项目。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-26 DOI: 10.1080/10428194.2025.2506502

Shelby Mestnik, Andrew R Marley, Zhanni Lu, Lucie M Turcotte, Erin Marcotte, Logan G Spector

{"title":"Childhood body mass index at diagnosis and its association with non-Hodgkin lymphoma in the United States: a children's oncology group data analysis project.","authors":"Shelby Mestnik, Andrew R Marley, Zhanni Lu, Lucie M Turcotte, Erin Marcotte, Logan G Spector","doi":"10.1080/10428194.2025.2506502","DOIUrl":"10.1080/10428194.2025.2506502","url":null,"abstract":"Childhood obesity has historically increased with time. Associations are noted between obesity and cancer in adults; but little investigation has been done in children. We conducted a matched case control study to assess the association between body mass index (BMI) and Non-Hodgkin Lymphoma (NHL) in children. Case information is from Children's Oncology Group and controls from National Health and Nutrition Examination Survey. There was no association between obesity and NHL overall, but patients less than 10 years, showed a positive association if outside of the normal BMI range, both obesity and underweight. Additionally, there was an association between NHL and underweight overall, in males, and in non-Hispanic/Latino children. Obesity showed an inverse association with NHL in females and children older than 10. We were not able to assess causality. Disease causing weight loss prior to diagnosis likely skewed baseline weights lower. Additional studies with BMI prior to diagnosis are needed.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1931-1936"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201. 伊鲁替尼加入标准调节和作为自体造血干细胞移植后复发或难治性活化b细胞型弥漫性大b细胞淋巴瘤的维持治疗：美国组间双盲随机III期研究联盟A051301/BMT-CTN 1201的初步分析。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-07-09 DOI: 10.1080/10428194.2025.2525982

Charalambos Andreadis, Olivia Bobek, Eric D Hsi, Timothy S Fenske, Patrick J Stiff, Brian T Hill, Susan M Geyer, Mitchell Horwitz, Farhad Khimani, Richard F Little, Shira N Dinner, Jonathan W Friedberg, Brad S Kahl, Miguel-Angel Perales, Steven M Devine, John P Leonard, Nancy L Bartlett

{"title":"Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.","authors":"Charalambos Andreadis, Olivia Bobek, Eric D Hsi, Timothy S Fenske, Patrick J Stiff, Brian T Hill, Susan M Geyer, Mitchell Horwitz, Farhad Khimani, Richard F Little, Shira N Dinner, Jonathan W Friedberg, Brad S Kahl, Miguel-Angel Perales, Steven M Devine, John P Leonard, Nancy L Bartlett","doi":"10.1080/10428194.2025.2525982","DOIUrl":"10.1080/10428194.2025.2525982","url":null,"abstract":"To improve outcomes in relapsed or refractory activated B-cell type Diffuse Large B-cell Lymphoma (ABC-DLBCL), we launched a randomized phase 3 trial evaluating 2-year progression free survival (2yPFS) with the addition of ibrutinib to autologous transplant. Patients received ibrutinib 560 mg or placebo with conditioning and for 12 additional cycles. Accrual was adversely affected by implementation of the ABC classifier in this setting and the changing treatment landscape of DLBCL. In all, 39 patients on ibrutinib and 38 on placebo were evaluable. 2yPFS was 57.6% on ibrutinib versus 40.8% on placebo (p = 0.09). We observed a higher incidence of grade ≥3 sepsis (10% vs 5%) and mucositis (13% vs. 3%) on ibrutinib but similar rates of atrial fibrillation. There were 4 fatalad verse events in the ibrutinib arm due to infection. Ibrutinib added to transplant may improve 2yPFS in relapsed/refractory ABC-DLBCL but future clinical trials should incorporate more efficient patient selection.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1903-1912"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12321088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Co-occurrence of aplastic anemia and NLPHL with full recovery after local resection and radiation. 再生障碍性贫血和NLPHL共存，局部切除和放疗后完全恢复。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-27 DOI: 10.1080/10428194.2025.2507194

Tzvika Porges, Kayed Al-Athamen, Yehonatan Sherf

引用次数: 0

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review. 接受t细胞定向治疗的多发性骨髓瘤患者发生第二原发恶性肿瘤的风险：一项系统综述。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-29 DOI: 10.1080/10428194.2025.2560085

Hyun Park, Julian Robinson, Cliona Flanagan, Charlotte Pawlyn, Graham Jackson, John R Jones

{"title":"The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review.","authors":"Hyun Park, Julian Robinson, Cliona Flanagan, Charlotte Pawlyn, Graham Jackson, John R Jones","doi":"10.1080/10428194.2025.2560085","DOIUrl":"https://doi.org/10.1080/10428194.2025.2560085","url":null,"abstract":"Whilst T-cell directed therapies have revolutionized the therapeutic landscape in triple-class refractory multiple myeloma, ongoing long-term safety concerns remain, including the risk of second primary malignancy (SPM) development. We systematically evaluated the incidence and distribution of SPMs in R/R MM patients post T-cell-directed therapy. MEDLINE, EMBASE, and Cochrane CENTRAL databases were searched for clinical trial and real-world studies reporting outcomes for patients infused with either chimeric antigen receptor (CAR) T-cell or bispecific antibody therapies reported until March 2025. Patient-specific characteristics and SPM outcomes were extracted from eligible studies with calculation of point estimate confidence intervals (CIs) achieved via the Clopper-Pearson Exact Method. A total of 12 studies (7 RCTs and 5 RWS) were eligible for analysis, encompassing a total of 2743 adult R/R MM patients. Eleven studies were related to CAR T-cell therapy, with only 1 study reporting on bispecific antibody therapy. The pooled SPM point estimate for CAR T-cell therapy was 6.3%, with hematological malignancies representing the most common subtype. This highlights the potential risk of SPMs in patients eligible for T-cell directed therapy. Further robust, prospective clinical trial and pharmacovigilance data will continue to inform the true level of risk in this cohort of patients.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms. 恶性组织细胞肿瘤中PD-L1的表达和对免疫检查点抑制剂治疗的反应。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-25 DOI: 10.1080/10428194.2025.2561114

Aishwarya Ravindran, Liuyan Jiang, Gordon J Ruan, Surendra Dasari, Jithma P Abeykoon, Saurabh Zanwar, Jason R Young, Corrie R Bach, Jonathan E McConathy, N Nora Bennani, Ronald S Go, Gaurav Goyal, Karen L Rech

{"title":"PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms.","authors":"Aishwarya Ravindran, Liuyan Jiang, Gordon J Ruan, Surendra Dasari, Jithma P Abeykoon, Saurabh Zanwar, Jason R Young, Corrie R Bach, Jonathan E McConathy, N Nora Bennani, Ronald S Go, Gaurav Goyal, Karen L Rech","doi":"10.1080/10428194.2025.2561114","DOIUrl":"https://doi.org/10.1080/10428194.2025.2561114","url":null,"abstract":"Malignant histiocytic neoplasms (MHN) are aggressive cancers without an established effective treatment. Recent studies have suggested possible role of immune checkpoint inhibitors (ICI), but predictors of response are unknown. We analyzed 26 MHNs to determine the frequency of PD-L1 expression and clinicopathologic correlates. PD-L1-assessment on tumor cells was manually scored negative or positive (≥1%). Median age at diagnosis was 59 years and PD-L1-positivity was seen in 73%. Those with ≥50% PD-L1 expression had better overall survival compared to PD-L1 < 50% (100% vs 42%; P-value:0.0324). The overall response rate (ORR) to ICI in six MHNs was 50%. A comprehensive literature review revealed ORR of 64% in 14 MHN patients treated with ICI. Combining patient and literature cohorts treated with ICI (N = 20), responders showed a higher median PD-L1 expression compared to non-responders (88% vs 30%; P-value: 0.0737). While ICI is promising in MHN-subset, larger cohorts need to be systematically investigated to analyze the long-term sustainability and efficacy with/without combination chemotherapy/radiation.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From dimensions through dynamics to outcomes - lymph nodes and skin assessments predict CTCL outcomes. 从维度到动态到结果-淋巴结和皮肤评估预测CTCL的结果。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-21 DOI: 10.1080/10428194.2025.2553863

Alexander Kaminsky, Lauren M Fahmy, Zaid Bilgrami, Hye Ryung Yang, Volkan Beylergil, Mengxi Zhou, Sara Suhl, Susan E Bates, Tito Fojo, Hao Yang, Lawrence H Schwartz, Larisa J Geskin

{"title":"From dimensions through dynamics to outcomes - lymph nodes and skin assessments predict CTCL outcomes.","authors":"Alexander Kaminsky, Lauren M Fahmy, Zaid Bilgrami, Hye Ryung Yang, Volkan Beylergil, Mengxi Zhou, Sara Suhl, Susan E Bates, Tito Fojo, Hao Yang, Lawrence H Schwartz, Larisa J Geskin","doi":"10.1080/10428194.2025.2553863","DOIUrl":"https://doi.org/10.1080/10428194.2025.2553863","url":null,"abstract":"Radiologic nodal staging in CTCL traditionally uses a 1.5 cm longest diameter (LDi) cutoff; however, this lacks validation and may misclassify risk. We conducted a retrospective analysis of 6,095 CT scans from 262 CTCL patients in the MAVORIC trial using unidimensional, bidimensional, and volumetric LN measurements and mSWAT scores. Optimal cutoffs were determined via ROC analysis and landmarking adjusted for informative censoring. Additionally, kinetic modeling growth rates (g) were calculated for both LN and skin scores. We demonstrated that LDi > 1.5 cm did not predict OS (p = 0.8). However, baseline volumetric cutoffs (3,945 mm3; AUC = 0.67) stratified OS (median 43.6 months vs NA, log-rank p = 0.035); post‑landmark analysis (6,930 mm3) enhanced discrimination. High g (volumetric or mSWAT) independently predicted shorter OS/PFS/TTF (p < 0.05). A combined model (volume + g) had C‑index 0.63 versus 0.60 for volume alone. We conclude that volumetric and dynamic metrics outperform conventional measures in predicting CTCL outcomes. Incorporating these methods into staging and trial criteria is warranted.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm. tagraxofusp单药治疗复发或难治性母细胞浆细胞样树突状细胞肿瘤的实际研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-09-18 DOI: 10.1080/10428194.2025.2553862

Emanuele Angelucci, Eric Deconinck, Tobias Matthieu Benoit, Krischan Braitsch, Cristina Papayannidis, Ann-Kristin Schmaelter, Dimoula Erakli, Michael Zuurman, Marco Herling

{"title":"Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.","authors":"Emanuele Angelucci, Eric Deconinck, Tobias Matthieu Benoit, Krischan Braitsch, Cristina Papayannidis, Ann-Kristin Schmaelter, Dimoula Erakli, Michael Zuurman, Marco Herling","doi":"10.1080/10428194.2025.2553862","DOIUrl":"https://doi.org/10.1080/10428194.2025.2553862","url":null,"abstract":"Patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) have limited treatment options. Tagraxofusp is the only drug approved for BPDCN. To provide real-world data on tagraxofusp in clinical practice, we report an analysis of safety and efficacy in adults who obtained tagraxofusp via a European named-patient program. Twenty-four patients (median age 68 years) with relapsed/refractory BPDCN received tagraxofusp 12 μg/kg intravenously days 1-5 of a 21-day cycle. Twenty patients (efficacy-evaluable) had a 65% overall response rate (ORR), 9.5-month median duration of response, 3.6-month median progression-free survival, and 8.4-month median overall survival (OS). Ten patients bridged to HSCT with a median OS not reached. There were no new safety signals. Capillary leak syndrome was manageable, mostly occurring during cycle one. These results support tagraxofusp for relapsed/refractory BPDCN after prior chemotherapy. Furthermore, the high transplant rate suggests tagraxofusp offers an opportunity for bridge to transplant in this difficult-to-treat population.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0